Source: Eur Respir J, 59 (2) 2102380; 10.1183/13993003.02380-2021



Rating:

Share or cite this content

Citations should be made in the following way:
Han-I Yeh, Tzyh-Chang Hwang. In vitro assessment of triple combination therapy for the most common disease-associated mutation in cystic fibrosis. Eur Respir J, 59 (2) 2102380; 10.1183/13993003.02380-2021

Member's Comments

No comment yet.

Related content which might interest you: A novel CFTR mutation found in a Chinese cystic fibrosis patient Source: Eur Respir J 2005; 26: Suppl. 49, 402s Year: 2005 Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient Source: Eur Respir J 2002; 19: 374-376 Year: 2002 Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles Source: ERJ Open Res, 5 (2) 00082-2019; 10.1183/23120541.00082-2019 Year: 2019 First identified “severe” mutations and extended rearrangements in the CFTR gene in Russian cystic fibrosis patients Source: Virtual Congress 2020 – Cystic fibrosis Year: 2020 Genotype specific therapies for cystic fibrosis Source: Annual Congress 2004 - New approaches to cystic fibrosis: from cells and molecules to novel therapies Year: 2004 Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis Source: Eur Respir J 2011; 37: 59-69 Year: 2011 Lumacaftor-Ivacaftor combination therapy in Phe508del homozygous CF patients with end-stage lung disease – preliminary results Source: International Congress 2017 – Cystic fibrosis: treatments and monitoring Year: 2017 Evaluation of MRP1-5 gene expression in cystic fibrosis patients homozygous for the ΔF508 mutation Source: Annual Congress 2003 - Cystic fibrosis: new genes, new controversies Year: 2003 Cystic fibrosis: prospects for therapy of some class 1 mutations Source: Annual Congress 2007 - Cystic fibrosis: will the new biology deliver? Year: 2007 Genotype/phenotype correlation of the G85E mutation in a large cohort of cystic fibrosis patients Source: Eur Respir J 2004; 23: 679-684 Year: 2004 Genotype-phenotype correlation in cystic fibrosis patients bearing a novel complex allele Source: Annual Congress 2011 - Cystic fibrosis: clinical and laboratory studies Year: 2011 Long-term outcomes and clinical worsening in cystic fibrosis patients with at least one residual function mutation Source: International Congress 2018 – Cystic fibrosis in adults: current research Year: 2018 CFTR gene mutations detected in Japanese individuals with cystic fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 716s Year: 2006 The cystic fibrosis airway milieu enhances rescue of F508del in a pre-clinical model Source: Eur Respir J, 52 (6) 1801133; 10.1183/13993003.01133-2018 Year: 2018 Targeting CFTR as a therapy for cystic fibrosis Source: Lung Science Conference 2010 - Biology of gene-environment interactions in the lung Year: 2010 Topical application of gentamicin causes a reduction of sweat ion concentration in cystic fibrosis patients carrying nonsense mutations Source: Eur Respir J 2001; 18: Suppl. 33, 9s Year: 2001 High morbidity and mortality in cystic fibrosis patients compound heterozygous for 3905insT and ΔF508 Source: Eur Respir J 2001; 17: 1181-1186 Year: 2001 Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: Evaluation of exacerbations and lung function Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring Year: 2016 Combination of ENaC and CFTR mutations may predispose to cystic fibrosis-like disease Source: Eur Respir J 2009; 34: 772 Year: 2009